Skip to content

Novavax boosts COVID-19 vaccine production capacity to 2B doses per year

September 15, 2020

Novavax (NASDAQ:NVAX) has amended its agreement with Serum Institute of India Private Limited (SIIPL), under which the latter will manufacture the antigen component of COVID-19 vaccine candidate NVX-CoV2373. The deal increases manufacturing capacity to more than 2B doses annually when all planned changes are implemented by mid-2021.

NVAX says the antigen component is being made at its site in Bohumil, Czech Republic, plus six other locations, including SIIPL.

The Matrix-M adjuvant is being made at three locations, including its site in Uppsala, Sweden.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: